Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

Rhea-AI Summary

Silo Pharma, Inc. (OTCQB: SILO) announced the issuance of U.S. Patent No. 11,174,287 for a novel homing peptide aimed at enhancing therapeutic targeting in the central nervous system (CNS). This advancement could improve pharmacological treatments, allowing for lower dosages and reduced side effects. CEO Eric Weisblum expressed optimism about expanding their intellectual property (IP) portfolio and the potential for this technology to transform treatment options for CNS disorders. The patent emphasizes the importance of targeting neuroinflammation in CNS tissues.

Positive

• Issuance of U.S. Patent No. 11,174,287 could enhance Silo Pharma's IP portfolio.
• Novel homing peptide may improve treatment targeting and efficacy in CNS disorders.

Negative

• None.

U.S. Patent and Trademark Office issued US Patent No. 11,174,287 investigation, detection, treatment or prevention of neuroinflammation

Englewood Cliffs NJ, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic announced the issuance of a patent relating to its University Maryland Baltimore licensed homing peptide.  The novel homing peptide can be used for enhanced targeting of therapeutic agents to the central nervous system. Silo Pharma’s licensed homing peptide can potentially improve pharmacological treatment of disease, lower effective dosages, thereby reducing side effects and toxicity. 

The present invention provides homing peptides that localize in CNS (central nervous system) tissue characterized by neuroinflammation and methods of using the same.

Eric Weisblum, Silo Pharma’s Chief Executive Officer commented on this key event. “We are pleased to receive this very important patent issuance to our expanding IP portfolio. Silo Pharma looks forward to further its studies with the objective of introducing improved and effective targeted therapeutic agents to treat millions of patients suffering with CNS disorders.  

About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com

Safe Harbor and Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:
Hayden IR
Brett Maas
646-536-7331
Email: brett@haydenir.com

FAQ

What is U.S. Patent No. 11,174,287 issued to Silo Pharma about?

The patent relates to a novel homing peptide that enhances targeting of therapeutic agents to the central nervous system, particularly for conditions involving neuroinflammation.

How does the homing peptide benefit Silo Pharma's therapy development?

The homing peptide may allow for lower dosages of therapeutic agents, reducing side effects and potentially improving treatment outcomes for patients with CNS disorders.

What are the implications of this patent for Silo Pharma's future studies?

The patent supports Silo Pharma's objective to develop effective targeted therapeutic agents for CNS disorders, opening new avenues for research and treatment.

When was U.S. Patent No. 11,174,287 issued to Silo Pharma?

The patent was issued on December 2, 2021.